Rheumatology: Current Research
Open Access
ISSN: 2161-1149 (Printed)
ISSN: 2161-1149 (Printed)
Mańczak M
Poland
Research Article
Biologics Treatment Limits Disease Activity and Bone Metabolism in Patients with Rheumatoid Arthritis
Author(s): Próchnicka RK, Gorycka PA, Mańczak M, Giemza FA, Wojciechowska M, Wojdasiewicz P, Maśliński S, Olesińska M and Szukiewicz DPróchnicka RK, Gorycka PA, Mańczak M, Giemza FA, Wojciechowska M, Wojdasiewicz P, Maśliński S, Olesińska M and Szukiewicz D
Introduction: Generalized bone loss in rheumatoid arthritis (RA) is multi-factorial, and can be divided into erosions of the joint and osteoporosis. Biomarkers of bone remodeling provide a dynamic view of the remodeling process and they contribute to a better understanding of bone physiology and the pathogenesis of metabolic bone diseases. To examine whether treatment with biologics agents reduces of disease activity and changes the markers of bone metabolism, including osteocalcin (OC), N-terminal propeptide of type I procollagen (PINP), cross-linked Cterminal telopeptide of type I collagen (CTX), receptor activator of the NF-κB ligand (RANKL) and osteoprotegerin (OPG).
Materials and methods: 125 patients with active RA, who were treated with DMARDs (44 patients) and biologics agents including 49 patients on Etanercept, 16 patients on.. View More»